E. coli Urinary Tract Infection Study

2023-509777-23-00 Protocol PP-EC-001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 5 sites · Protocol PP-EC-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 36
Countries 1
Sites 5

Bacterial urinary infection

Key facts

Sponsor
Phagenix
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Decision date (initial)
2024-05-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Bacterial urinary infection

VersionLevelCodeTermSystem organ class
21.1 PT 10029279 Neurogenic bladder 100000004857
20.0 PT 10054088 Urinary tract infection bacterial 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Phagenix

2 Total trials
Commercial
Sponsor organisation
Phagenix
Address
60 Avenue Rockefeller
City
Lyon
Postcode
69008
Country
France

Scientific contact point

Organisation
Phagenix
Contact name
Chief Medical Officer

Public contact point

Organisation
Phagenix
Contact name
Chief Medical Officer

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 36 5
Rest of world 0

Investigational sites

France

5 sites · Authorised, recruitment pending
Bicetre Hospital
Clinical pharmacology - CRC, 78 Rue Du General Leclerc, 94275, Le Kremlin Bicetre Cedex
Centre Hospitalier Universitaire De Nantes
Urology, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire De Rennes
Urology, 2 Rue Henri Le Guilloux, 35000, Rennes
Centre Hospitalier Universitaire De Nimes
Infectious deseases, Place Du Professeur Robert Debre, 30900, Nimes
Raymond Poincare Hospital
Infectious deseases, 104 Boulevard Raymond Poincare, 92380, Garches

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-08 France Acceptable with conditions
2024-04-29
2024-05-06
2 SUBSTANTIAL MODIFICATION SM-1 2026-04-23 France Acceptable
2026-04-27
2026-05-06
3 SUBSTANTIAL MODIFICATION SM-2 2026-05-11 France Acceptable
2026-05-21
2026-05-21